Maxcyte Inc stock is traded at $1.20, with a volume of 191,237. It is up +1.69% in the last 24 hours and down -7.69% over the past month. MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Previous Close:
$1.18
Open:
$1.19
24h Volume:
191,237
Relative Volume:
0.11
Market Cap:
$123.90M
Revenue:
$32.29M
Net Income/Loss:
-$39.12M
P/E Ratio:
-
EPS:
-$0.3669
Net Cash Flow:
-$29.51M
1W Performance:
+6.19%
1M Performance:
-7.69%
6M Performance:
+15.38%
1Y Performance:
-26.38%
1-Day Range:
$1.18$1.26
1-Week Range:
$1.02$1.28
52-Week Range:
$0.6434$1.81
Maxcyte Inc Stock (MXCT) Company Profile
Name
Maxcyte IncSector
HealthcareIndustry
Medical DevicesPhone
301-517-5556Address
9713 KEY WEST AVENUE,, ROCKVILLE, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS